discussing targeted treatment with parp inhibitors for brca-mutant patients across tumor types
Published 5 years ago • 55 plays • Length 1:58Download video MP4
Download video MP3
Similar videos
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
3:48
targeted therapies for patients with ovarian cancer who have brca-mutated tumors
-
1:27:32
target practice: understanding how parp inhibitors take aim at ddr mutations across solid tumors
-
0:54
parp inhibitors advance beyond treatment of brca1/2-mutant gynecologic cancers
-
8:50
case 4: chemotherapy or parp inhibitors for brca tnbc
-
7:04
testing for brca germline mutations in the clinic and the mechanism of action of parp inhibitors
-
11:49
brca & parp inhibitors: targeted chemotherapy | #markscholzmd #alexscholz @pcri
-
3:46
case 4: parp inhibitors for treating brca triple-negative breast cancer
-
2:15
parp inhibitors in metastatic breast cancer: where are we now?
-
4:19
treating brca breast cancer with parp inhibition
-
6:35
treatment options for patients with brca1/2
-
1:13
addressing the role of parp inhibitors in different breast cancer settings
-
47:27
parp inhibitors: a breakthrough in cancer therapy?
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
0:55
overcoming resistance to parp inhibitors in ovarian cancer
-
1:32:38
managed care implications of the expanding role of parp inhibitors in oncology
-
4:17
case 2: olaparib in brca-mutated ovarian cancer
-
3:27
tripathy discusses a study of talazoparib in brca-mutated advanced breast cancer
-
3:41
case 2: treating brca-mutated ovarian cancer